Is Akums Drugs & Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Akums Drugs & Pharmaceuticals Ltd is a good quality company .

Is Akums Drugs & Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Akums Drugs & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Akums Drugs & Pharmaceuticals share price return in the past 10 years?

Data is not available for this company

Is Akums Drugs & Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Akums Drugs & Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Akums Drugs & Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Akums Drugs & Pharmaceuticals
Brand: Akums Drugs & Pharmaceuticals

BSE: 544222 | NSE: AKUMS | Pharmaceuticals & Drugs | Small Cap

Place order

Akums Drugs & Pharmaceuticals Share Price

₹609.95 29.00 4.99%
as on 21-Nov'24 15:49

10 Year X-Ray of Akums Drugs & Pharmaceuticals:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	25.8%	19.2%	8.5%	6.6%	13.8%	13.7%	9.8%	-29.1%	-73.8%	42.8%	-
Value Creation Index ⓘ	0.9	0.4	-0.4	-0.5	0.0	0.0	-0.3	-3.2	-6.5	2.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	897	967	564	628	596	683	737	837	1,162	1,287	1,287
Sales YoY Gr.	-	7.8%	-41.6%	11.3%	-5.2%	14.7%	7.9%	13.6%	38.8%	10.7%	-
Adj EPS ⓘ	8.2	6.6	3.6	2.5	5.2	5.7	3.6	2	-27.1	15.4	8
YoY Gr.	-	-19.7%	-45.7%	-30.3%	111.3%	9%	-37.8%	-42.5%	-1427%	NA	-
BVPS (₹) ⓘ	41.6	48.1	51.5	54.1	59.4	65.1	49.8	39.6	13	21.8	0
Adj Net Profit ⓘ	106	84.7	46.1	32.1	67.7	73.9	50.8	29.2	-387	220	125
Cash Flow from Ops. ⓘ	29	168	3.4	44.1	71.4	2.8	-21.8	55.6	228	94	-
Debt/CF from Ops. ⓘ	4.6	0.6	18	1.3	0.5	18.2	-1.7	0.4	0.5	1.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	4.1%	16.7%	20.4%	10.7%
Adj EPS ⓘ	7.3%	24%	63%	NA
BVPSⓘ	-6.9%	-18.2%	-24.1%	67.9%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	21.8	14.6	7.2	4.7	9.2	9.2	6.5	4.6	-102.9	88.4	73.2
Op. Profit Mgn % ⓘ	15.8	12.4	7.6	4.7	12.6	12	5.4	3.2	-31.2	18.3	-0.8
Net Profit Mgn % ⓘ	11.8	8.8	8.2	5.1	11.4	10.8	6.9	3.5	-33.3	17.1	9.8
Debt to Equity ⓘ	0.3	0.2	0.1	0.1	0	0.1	0.1	0	0.7	0.5	0
Working Cap Days ⓘ	196	222	386	346	406	407	458	417	355	404	77
Cash Conv. Cycle ⓘ	73	74	117	102	92	88	93	82	62	59	50

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 73.20%

Sales growth is growing at healthy rate in last 3 years 20.42%

Sales growth is not so good in last 4 quarters at -6.50%

Latest Financials - Akums Drugs & Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	8	-0.3
TTM Sales (₹ Cr.)	1,287	4,178
BVPS (₹.) ⓘ	0	180.1
Reserves (₹ Cr.) ⓘ	2,204	2,803
P/BV ⓘ	0.00	3.23
PE ⓘ	72.90	0.00

From the Market
52 Week Low / High (₹)	527.00 / 1174.85
All Time Low / High (₹)	553.30 / 1174.85
Market Cap (₹ Cr.)	9,144
Equity (₹ Cr.)	31.5
Face Value (₹)	2
Industry PE ⓘ	43

Management X-Ray of Akums Drugs & Pharmaceuticals:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Akums Drugs & Pharmaceuticals

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Akums Drugs & Pharmaceuticals

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	897	967	564	628	596	683	737	837	1,162	1,287
Operating Expenses ⓘ	755	847	522	599	521	601	697	811	1,524	1,051
Manufacturing Costs	32	41	42	47	39	44	58	51	72	84
Material Costs	609	674	357	428	360	418	466	524	768	788
Employee Cost	92	110	102	100	94	103	124	123	136	147
Other Costs ⓘ	23	23	21	24	27	36	49	113	548	31
Operating Profit ⓘ	142	120	43	29	75	82	40	27	-362	236
Operating Profit Margin (%)	15.8%	12.4%	7.6%	4.7%	12.6%	12.0%	5.4%	3.2%	-31.2%	18.3%
Other Income ⓘ	21	38	44	43	55	57	66	55	58	102
Interest ⓘ	8	14	8	5	3	4	4	1	4	13
Depreciation ⓘ	14	24	22	24	23	23	25	26	28	30
Exceptional Items ⓘ	0	0	-3	0	0	0	0	-249	0	-145
Profit Before Tax ⓘ	141	119	54	43	105	112	76	-195	-335	150
Tax ⓘ	35	35	10	11	37	37	25	-50	47	25
Profit After Tax	106	85	44	32	68	75	51	-145	-382	125
PAT Margin (%)	11.8%	8.8%	7.8%	5.2%	11.4%	11.0%	6.9%	-17.4%	-32.9%	9.7%
Adjusted EPS (₹)	8.2	6.6	3.4	2.5	5.2	5.8	3.6	-10.2	-26.7	8.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	537	622	666	699	767	842	712	567	186	312
Share Capital ⓘ	1	1	1	1	1	1	1	1	14	29
Reserves ⓘ	536	621	665	698	766	841	711	566	171	283
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	126	94	50	47	33	51	36	23	122	142
Long Term Debt	2	24	12	0	0	0	0	0	0	22
Short Term Debt	125	70	38	47	33	51	36	23	122	121
Trade Payables	111	57	41	43	86	69	108	90	252	178
Others Liabilities ⓘ	77	93	92	71	74	85	570	585	1,254	1,259
Total Liabilities ⓘ	851	867	849	860	960	1,046	1,426	1,265	1,814	1,891
Fixed Assets
Gross Block	324	322	335	353	367	389	417	442	470	513
Accumulated Depreciation	65	84	104	126	147	169	191	213	237	260
Net Fixed Assetsⓘ	260	237	231	227	219	220	226	229	233	253
CWIP ⓘ	0	0	0	0	0	0	1	1	1	16
Investmentsⓘ	4	4	22	21	21	20	81	149	141	139
Inventories	161	92	120	88	121	106	123	96	179	197
Trade Receivables	191	143	116	120	121	159	178	212	304	256
Cash Equivalents	21	2	2	3	0	4	72	1	26	9
Others Assetsⓘ	214	389	357	401	477	537	745	576	930	1,020
Total Assets ⓘ	851	867	849	860	960	1,046	1,426	1,265	1,814	1,891

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	29	168	3	44	71	3	-22	56	228	94
PBT ⓘ	141	119	54	43	105	112	76	-195	-335	150
Adjustment ⓘ	7	9	-8	-9	-17	-25	-26	-19	-12	-19
Changes in Working Capital ⓘ	-89	55	-14	19	4	-49	-23	-28	100	-82
Tax Paid ⓘ	-30	-16	-28	-8	-19	-33	-46	-5	-7	-30
Cash Flow From Investing Activity ⓘ	-81	-141	44	-35	-46	-15	-242	-100	-298	-202
Capex	-13	-1	-34	-18	-15	-23	-31	-29	-28	-103
Net Investments	0	0	0	0	0	1	0	-19	0	0
Others ⓘ	-68	-139	78	-17	-31	7	-211	-52	-270	-99
Cash Flow From Financing Activityⓘ	69	-44	-47	-8	-28	15	302	3	95	90
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	320	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	-12	0	0	0	0	0	0
Interest Paid ⓘ	0	-14	-8	0	0	0	-2	-1	-2	-11
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	69	-30	-39	4	-28	15	-16	3	97	101
Net Cash Flow ⓘ	17	-17	0	1	-2	3	38	-42	25	-18

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	21.83	14.61	6.83	4.75	9.24	9.3	6.54	-22.73	-101.46	50.47
ROCE (%)	25.75	19.18	8.5	6.57	13.83	13.69	9.77	-29.06	-73.83	42.75
Asset Turnover Ratio	1.18	1.13	0.66	0.74	0.66	0.68	0.6	0.62	0.75	0.69
PAT to CFO Conversion(x)	0.27	1.98	0.07	1.38	1.04	0.04	-0.43	N/A	N/A	0.75
Working Capital Days
Receivable Days	71	63	83	68	74	75	83	85	81	79
Inventory Days	55	48	68	60	64	61	57	48	43	53
Payable Days	66	46	50	36	65	67	69	69	81	100

Akums Drugs & Pharmaceuticals Ltd Stock News

Akums Drugs & Pharmaceuticals Ltd FAQs

What is the share price of Akums Drugs & Pharmaceuticals?

Company share prices are keep on changing according to the market conditions. The closing price of Akums Drugs & Pharmaceuticals on 21-Nov-2024 15:49 is ₹610.0.

What is the market cap of Akums Drugs & Pharmaceuticals?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 15:49 the market cap of Akums Drugs & Pharmaceuticals stood at ₹9,143.8.

What is the P/E ratio of Akums Drugs & Pharmaceuticals?

The latest P/E ratio of Akums Drugs & Pharmaceuticals as of 21-Nov-2024 15:49 is 72.90.

What is the P/B ratio of Akums Drugs & Pharmaceuticals?

The latest P/B ratio of Akums Drugs & Pharmaceuticals as of 21-Nov-2024 15:49 is 0.00.

What is the 52-week high and low of Akums Drugs & Pharmaceuticals?

The 52-week high of Akums Drugs & Pharmaceuticals is ₹1,174.9 and the 52-week low is ₹527.0.

What is the TTM revenue of Akums Drugs & Pharmaceuticals?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Akums Drugs & Pharmaceuticals is ₹1,287 ( Cr.) .

About Akums Drugs & Pharmaceuticals Ltd

The company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of ‘Akums Drugs and Pharmaceuticals Limited’, pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi (RoC). The company received a certificate of commencement of business issued by the RoC dated May 13, 2004.

Established in 2004, Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, the company owns the intellectual property for the manufacturing processes of several of its formulations, and its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Some of its other services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to its core CDMO business, it is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).

Business area of the company

As a CDMO, the company produces an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. It also engages in the marketing of trade generic and products under its own brand through distributors and alternative channels across India.

Key Awards and accreditations

2018: Received India Pharma Leader Award by Government of India.
2019: Received India Pharma Leader Award by Government of India.
2021: Award for India Pharma Award for Excellence in Contract Research and Manufacturing by Informamarkets.
2022: Award for Excellence in R&D and Innovation by ET Ascent.
2022: Awarded the International Healthcare award as Pharmaceutical Company of the Year in contract manufacturing by Times Cyber Media.
2022: Awarded the Excellence in Operations – Manufacturing by CPHI Awards.
2022: Awarded Asia’s Pharma Excellence Awards in Innovation in Nutraceutical, Cosmetic and Wellness Award by CMO Asia.
2023: Awarded Dream Employer of the Year by Times Ascent.
2023: Awarded the Excellence Award in Nutraceutical category by IHW Council.
2023: Award for the best brand based in North India by Exchange4Media.
2023: Awarded the best Technology Adaption – Cash Management Services by HDFC Bank.
2023: Awarded 2nd Runner up in Best Trademarks portfolio by CII Industrial Intellectual Property Awards.
2023: Awarded the Excellence in Formulations by India Pharma World Awards, The Economic Times.
2023: Awarded the Most Admired Quality Pharmaceutical Manufacturer of India 2023 by Observe Now.
2023: Awarded the Certificate of Appreciation for Excellence in Innovative Formulations – Nutraceutical and Wellness Award by Food Safety and Nutrition Summit and Awards 2023.

Major events and milestones

2004: Incorporation of the company.
2004: Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand.
2007: Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand.
2009: Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals.
2010: Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
2010: Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
2010: Incorporated Akumentis Healthcare Limited to venture into branded formulations.
2011: Innovated bi-layered sustained release tablets for the first time.
2012: Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities.
2013: Innovated tablet-in-tablet sustained release tablets for the first time.
2013: Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities.
2013: Expanded into the African market.
2015: Expanded into the Asian market.
2015: Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market.
2016: Maxcure Nutravedics Limited received US-NSF certification.
2019: Investment by Ruby QC Investment Holdings Pte. Ltd. in the company to become a minority shareholder.
2021: Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs.
2021: Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited.
2022: Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets.
2022: Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
2023: Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
2023: Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited.